EUVIMEDEUVIMED entdecken
Vergleichsstudie

Environmental Impact Assessment of Intravenous Versus Subcutaneous Monoclonal Antibodies: A Carbon Footprint Analysis

Michiel Zietse iD, Thirza Kooijman iD, Ruben Malmberg iD, Leontine E A M M Spierings iD, Agnes Jager iD, Ron H J Mathijssen iD, Roelof W F van Leeuwen, Frederick W Thielen iD

JCO Oncology Practice · 2025-09 · 21 (9) · 1287-1295

DOI: 10.1200/op-24-00804 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift JCO Oncology Practice, 2025-09. Verfasst von Michiel Zietse und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, the Netherlands. Hauptthemen laut MEDLINE: Carbon Footprint, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 44 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE The development of subcutaneous (SC) formulations for monoclonal antibodies (mAbs), as an alternative to conventional intravenous (IV) infusion, represents a shift in health care delivery. The relative environmental impact of these two administration methods is not well understood. Minimizing the environmental footprint of health care is crucial due to its substantial contribution to greenhouse gas (GHG) emissions. This study compared the carbon footprint of SC and IV administration using pertuzumab/trastuzumab as a case example. METHODS A Life Cycle Assessment was conducted to compare the environmental impacts of IV versus SC administration of pertuzumab/trastuzumab, focusing on climate change impacts expressed in carbon dioxide-equivalents (CO 2 e). The analysis included emissions from single-use medical equipment, drug manufacturing, hospital operations, patient and staff transportation, and waste disposal. RESULTS SC pertuzumab/trastuzumab resulted in slightly higher GHG emissions than IV administration, with 47.2 kg CO 2 e for loading doses compared with 45.9 kg CO 2 e, and 33.6 kg CO 2 e for maintenance doses compared with 32.9 kg CO 2 e. This increase was primarily due to the higher dosage required for SC delivery, with mAb production contributing the most to emissions. Nonetheless, SC administration reduced the use of single-use medical equipment and treatment-related energy consumption in health care facilities. Switching to SC pertuzumab/trastuzumab administration in the Netherlands in 2022 would have increased annual CO 2 e emissions by 12.2 tons, equivalent to driving 63,212 km in a petrol-powered car. CONCLUSION Both IV and SC administration routes of mAbs have substantial environmental impacts, dominated by mAb production emissions. This research provides a framework for assessing the environmental impact of health care technologies and underscores the importance of integrating environmental considerations into health technology assessments to mitigate the significant contribution of health care to global GHG emissions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carbon FootprintAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedHumansInjections, SubcutaneousTrastuzumabAdministration, Intravenous

Substanzen

Antibodies, MonoclonalTrastuzumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, the Netherlands.
  • Department of Internal Medicine, Alrijne Hospital, Leiderdorp, the Netherlands.
  • Department of Medical Oncology, Erasmus University Medical Centre, Rotterdam, the Netherlands.
  • Department of Pharmacy, Treant Healthgroup, Emmen, the Netherlands.
  • Department of Health Technology Assessment, Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, the Netherlands.
  • Erasmus Center for Health Economics Rotterdam (EsCHER), Erasmus University Rotterdam, Rotterdam, the Netherlands.

ORCID-Profile: Michiel Zietse, Thirza Kooijman, Ruben Malmberg, Leontine E A M M Spierings, Agnes Jager, Ron H J Mathijssen, Frederick W Thielen

Zitieren

APA

Zietse, M., Kooijman, T., Malmberg, R., Spierings, L. E. A. M. M., Jager, A., Mathijssen, R. H. J., van Leeuwen, R. W. F., & Thielen, F. W. (2025). Environmental Impact Assessment of Intravenous Versus Subcutaneous Monoclonal Antibodies: A Carbon Footprint Analysis. JCO Oncology Practice, 21(9), 1287-1295. https://doi.org/10.1200/op-24-00804

Vancouver

Zietse M, Kooijman T, Malmberg R, Spierings LEAMM, Jager A, Mathijssen RHJ, et al. Environmental Impact Assessment of Intravenous Versus Subcutaneous Monoclonal Antibodies: A Carbon Footprint Analysis. JCO Oncology Practice. 2025;21(9):1287-1295. doi:10.1200/op-24-00804

BibTeX
@article{Zietse2025,
  author = {Zietse, Michiel and Kooijman, Thirza and Malmberg, Ruben and Spierings, Leontine E A M M and Jager, Agnes and Mathijssen, Ron H J and van Leeuwen, Roelof W F and Thielen, Frederick W},
  title = {Environmental Impact Assessment of Intravenous Versus Subcutaneous Monoclonal Antibodies: A Carbon Footprint Analysis},
  journal = {JCO Oncology Practice},
  year = {2025},
  volume = {21},
  number = {9},
  pages = {1287--1295},
  doi = {10.1200/op-24-00804}
}
Kostenlos starten →